Attention Seeking Stock: Zomedica Corp. (AMEX:ZOM)

Zomedica Corp. (AMEX:ZOM) with the stream of -31.92% in the last hour of trading session.

Zomedica Corp. (ZOM) shares fell -31.92% to close at $0.89. About 188,807,337 million shares traded hands on 114.87M trades for the day, compared with an average daily volume of 114.87M shares out of a total float of 539.13M. After opening the trading day at $1.14, shares of Zomedica Corp. stayed within a range of $0.81 to $1.20.

With today’s loss, Zomedica Corp. now has a market cap of $605.96M. Shares of Zomedica Corp. have been trading within a range of $0.063 and $1.48 over the last year, and it had a 50-day SMA of $312.85% and a 200-day SMA of $425.32%.

Zomedica Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. Its lead drug product candidate is ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies. The company is also developing ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. It has a collaboration agreement with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.

The PEG ratio is used to determine a stock’s value while taking the company’s earnings growth into account, and is considered to provide a more complete picture than the P/E ratio. Last traded has a PEG ratio of 0 where as its P/E ratio was 0. The overall volume in the last trading session was 188,807,337 shares.

Important Results:

Zomedica Corp. has P/S value of 0 while its P/B esteem remains at 16.25. Likewise, the company has Return on Assets of -63.30%, Return on Equity of -159.30% and Return on Investment of 0. The company demonstrates Gross Margin and Operating Margin of 0 and 0 respectively.

ZOM’s price to sales ratio for trailing twelve months was 0 and price to book ratio for most recent quarter was 16.25, whereas price to cash per share for the most recent quarter was 11.65. The Company’s price to free cash flow for trailing twelve months was recorded as 0.

Historical Performances to Consider:

The Stock’s performances for Monthly, weekly, half-yearly, quarterly & year-to-date are mentioned below:-

On a Monthly basis the stock was 710.47%. On a weekly basis, the stock remained 196.13%. The half-yearly performance for the stock has 725.40%, while the quarterly performance was 1397.70%. Looking further out we can see that the stock has moved 463.75% over the year to date. Other technical indicators are worth considering in assessing the prospects for EQT. RSI for instance was stand at 67.55.

Jake Charles

About Jake Charles

This is Jake Charles, a Senior News Writer for “Stocks Equity”. I covers “Active Stocks” sector and writes about trending Active Hot companies from an exclusive and “out of the box” perspective. I worked independently as a self motivator and with the financial institute as financial adviser to invest in the Active sector for over 9 years in the developing countries by introducing new phases and ways to improve in this sector. I like to travel all over the globe to get new experience and provide by best services to the companies. As an advisor I like to work with new people to share and explore new ideas keeping in view minimizing the operating cost and giving the best final product through new technology and minimizing the time of development.

View all posts by Jake Charles →

Leave a Reply

Your email address will not be published. Required fields are marked *